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Abstract
Methotrexate is an anti-folate medication that is associated with increased risk of multiple birth 
defects. Using data from the National Birth Defects Prevention Study, a case-control study of 
major birth defects in the United States, we examined mothers exposed to methotrexate. The study 
population included mothers of live-born infants without major birth defects (controls) and 
mothers of fetuses or infants with a major birth defect (cases), with expected dates of delivery 
between October 1997 and December 2009. Mothers of cases and controls were asked detailed 
questions concerning pregnancy history, demographic information, and exposures in a telephone 
interview. Approximately 0.06% (n=16/27,623) of case and 0.04% (n=4/10,113) of control 
mothers reported exposure to methotrexate between three months prior to conception through the 
end of pregnancy. Of the 16 case infants, 11 (68.8%) had a congenital heart defect (CHD). The 
observed CHDs included atrial septal defects, tetralogy of Fallot, valvar pulmonary stenosis, 
ventricular septal defects (VSDs), and total anomalous pulmonary venous return. One case infant 
had microtia in addition to a VSD and another had VACTER association. Exposed cases without a 
CHD had one of the following birth defects: cleft palate, hypospadias, congenital diaphragmatic 
hernia, or craniosynostosis. Based on a limited number of methotrexate-exposed mothers, our 
findings support recent case reports suggesting an association between early pregnancy exposure 
to methotrexate and CHDs. Because of the rarity of maternal periconceptional exposure to 
methotrexate, long-term, population-based case-control studies are needed to confirm these 
findings and better evaluate the association between methotrexate and birth defects.
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Methotrexate is a successful and widely used medication for cancer chemotherapy and a 
variety of other conditions [Lloyd et al., 1999]. Methotrexate is a folic acid antagonist that 
inhibits dihydrofolate reductase, thus blocking the synthesis of thymidine and inhibiting 
DNA synthesis. In addition to the treatment of malignancy, methotrexate has been used to 
treat rheumatic, dermatological, autoimmune, and inflammatory disorders, and in the 
termination of pregnancy [Lloyd et al., 1999]. Methotrexate has also become widely used in 
the successful non-surgical management of ectopic pregnancy [Richardson, 2012].
While methotrexate is a successful therapeutic agent, it also has potential deleterious effects, 
and methotrexate use is contraindicated during pregnancy. However, fetal exposure can 
occur, for example, as a result of the failed termination of a misdiagnosed ectopic 
pregnancy. The use of methotrexate by women of child-bearing age may be problematic as 
there have been many case reports of congenital malformations attributed to the use of folic 
acid antagonists during pregnancy [Milunsky et al., 1968]. Some authors have described a 
complex association of congenital malformations as “methotrexate embryopathy” [Chapa et 
al., 2003, Addar, 2004, Seidahmed et al., 2006]. Several previous literature reviews 
examined case reports of methotrexate use during pregnancy [Milunsky et al., 1968, 
Feldkamp and Carey, 1993, Hyoun et al., 2012]. The 1993 and 2012 reviews suggested 
specific malformations are associated with methotrexate exposure between six and eight 
weeks of gestation. However, recent case reports suggest additional malformations, 
including congenital heart defects (CHD), may be associated with exposure outside of the 
proposed sensitive period [Piggott et al., 2011]. In particular, recent case reviews reporting 
methotrexate exposure prior to six weeks gestation suggest the possibility of a distinct early-
exposure syndrome. Historically, descriptions of methotrexate embryopathy have not 
emphasized CHDs; however, tetralogy of Fallot and other neural crest cell-related 
abnormalities may be features of this early syndrome [Piggott et al., 2011, Poggi and 
Ghidini, 2011, Hyoun et al., 2012]. These reports suggest that the embryopathy attributable 
to methotrexate should be expanded beyond what was originally described [Nguyen et al., 
2002]. The objective of this study was to use a case-series approach to examine clinical 
information on case and control infants with maternal methotrexate exposure and to describe 
use of the medication during pregnancy.
MATERIALS AND METHODS
We examined data from the National Birth Defects Prevention Study (NBDPS), a multi-
center case control study of major, structural birth defects conducted in ten U.S. states. 
Institutional Review Boards at each site have approved the study. Study methods for 
recruitment of participants and data collection for the NBDPS have been described in detail 
elsewhere [Yoon et al., 2001, Rasmussen et al., 2003]. NBDPS cases include infants with 
major birth defects identified through population-based surveillance systems at each site. 
Infants with birth defects with a known etiology, including those with recognized 
chromosomal syndromes or single-gene disorders, are excluded. NBDPS controls, live-born 
infants with no major birth defects, were selected at random from the same ascertainment 
area as case infants using birth certificates or birth hospital records. Our study population 
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included mothers of cases, including live born infants, fetal deaths, and pregnancy 
terminations, and mothers of controls with estimated dates of delivery (EDD) between 
October 1, 1997 and December 31, 2009.
Mothers of case and control infants participated in a computer-assisted telephone interview, 
which included detailed questions concerning pregnancy history, demographic information, 
and exposures that occurred from three months prior to conception through the end of the 
pregnancy. Mothers were interviewed in English or Spanish between six weeks and 24 
months after their EDD. Mothers had two opportunities to report methotrexate exposure 
during the interview. First, mothers were asked if they had any “other chronic diseases or 
illnesses,” at which time interviewers could probe for report of conditions including 
rheumatoid arthritis, psoriasis, and lupus. Then mothers were asked to provide information 
on any medication(s) used to treat the reported condition. Secondly, mothers were 
questioned about use of a list of specific medications, which included “methotrexate,” but in 
these instances were not asked for indication.
Cases and controls in which the mother reported any exposure to methotrexate from three 
months prior to pregnancy through the end of the pregnancy were included in this study. A 
clinical geneticist and a pediatrician trained in cardiology reviewed the abstracted clinical 
records for each case infant. Clinical records for control infants were not available for 
review because infants with major birth defects are ineligible to be NBDPS controls 
[Cogswell et al., 2009]. Available information was also examined on the indication for use, 
the timing, frequency, and duration of methotrexate exposure during pregnancy as well as 
information on other possible risk factors for defects, including maternal age at delivery, 
race/ethnicity, pre-gestational or gestational diabetes, body mass index, and use of a folic 
acid-containing multivitamin.
Although the NBDPS is a case-control study with over 27,000 case and 10,000 control 
mothers, the minimum detectable odds ratio for the association between any methotrexate 
exposure and all birth defects combined was 3.8 [Dupont and Plummer, 1990]. However, 
because the etiology of individual birth defects varies, it is preferable to examine 
associations for each phenotype. Minimum detectable odds ratios ranged from 7.7 for 
secundum atrial septal defect, one of the most common birth defect phenotypes in the 
NBDPS, to 13.8 for congenital diaphragmatic hernia, one of the more rare defects we 
observed. Additionally, it would be preferable to examine associations by trimester and to 
control for potential confounders, which would further increase the minimum detectable 
odds ratios. Therefore, due to the rarity of this exposure and the specific birth defect 
phenotypes observed we elected to present a descriptive review of the characteristics of 
methotrexate-exposed mothers and the birth defects of their offspring, where applicable.
RESULTS
Approximately 0.06% (n=16/27,623) of case mothers and 0.04% (n=4/10,113) of control 
mothers reported exposure to methotrexate between three months prior to conception 
through the end of pregnancy. Ten of the case mothers reported methotrexate use during the 
first trimester, five mothers reported only preconceptional use, and one mother reported 
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methotrexate use after the first trimester (Table I). Two of the four control mothers reported 
only preconceptional use of methotrexate and two reported methotrexate use during the 
preconceptional period through the second week of pregnancy. The indication for 
methotrexate use was not reported in most cases, but indications that were reported included 
systemic lupus erythematosus, polyarticular juvenile rheumatoid arthritis, and a neoplasm of 
the endocrine glands.
Several maternal and infant characteristics of exposed cases and controls were assessed. The 
mean maternal age was 31 years for cases (range 22–39 years) and 33 years for controls 
(range 29–36 years). The majority of mothers were non-Hispanic white (cases, n=8; 
controls, n=4), had at least some college education (cases, n=14; controls, n=4), and were 
overweight or obese (body mass index >25 kg/m2; cases, n=10; controls, n=3). The desire to 
become pregnant at the time of conception was similar between case and control mothers (6 
of 16 case mothers, 2 of 4 control mothers). All cases were live-born except for one fetus 
that was electively terminated at 22 gestational weeks. Among live-born infants, the mean 
gestational age was 36.3 weeks (standard deviation (SD) 3.1) and 37.3 weeks (SD 2.1) for 
cases and controls, respectively; the mean birth weight was 2,688g (SD 822.7) and 2,753g 
(SD 648.8) for cases and controls, respectively.
The exposed cases had a variety of birth defects (Table I). Among the 16 case infants whose 
mother reported use of methotrexate at any time, 11 (68.8%) had a CHD. In comparison, 
approximately 39.9% of all NBDPS cases have a CHD. The observed CHDs included atrial 
septal defects, tetralogy of Fallot, valvar pulmonary stenosis, ventricular septal defects, and 
total anomalous pulmonary venous return. Exposure timing for cases with CHD varied. All 
cases that were exposed during the preconceptional period and the case exposed in the 
second trimester had at least one CHD, while five of 10 cases exposed during the first 
trimester had CHD. Other defects included cleft palate, hypospadias, congenital 
diaphragmatic hernia, craniosynostosis, and microtia.
Among cases with CHD, six of 11 mothers began use of folic acid-containing multivitamins 
after the first month of pregnancy; three of the five mothers of infants who reported first-
trimester exposure of methotrexate did not begin use of folic acid-containing multivitamins 
until at least the second month of pregnancy. Among case infants without CHD, four of five 
mothers reported use of folic acid-containing multivitamins beginning in the 
preconceptional period. All of the mothers of controls reported use of folic acid-containing 
multivitamins from the preconceptional period through the end of pregnancy.
DISCUSSION
Our finding of CHDs and other birth defects among infants of methotrexate-exposed 
mothers adds to the literature, suggesting a multi-organ embryopathy may be associated with 
early exposure to methotrexate [Piggott et al., 2011, Poggi and Ghidini, 2011, Hyoun et al., 
2012]. Although five of the case mothers reported only preconceptional use of methotrexate, 
preconceptional use may result in fetal exposure during the first trimester of pregnancy due 
to variability in red blood cell elimination of methotrexate metabolites. Wide inter-patient 
variability in the accumulation and elimination of oral methotrexate from red blood cells has 
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been observed in rheumatoid arthritis patients, with the half-life of elimination ranging from 
approximately one week to more than 13 weeks [Dalrymple et al., 2008]. Similarly, a 
recently developed population pharmacokinetic model of low-dose methotrexate and 
corresponding red blood cell metabolites, specifically polyglutamated metabolites 
MTXGlu2–5, highlights the complex and variable nature of methotrexate metabolism [Korell 
et al., 2013]. Polyglutamated forms of methotrexate have been shown to persist long term 
within cells of the liver and have also been associated with a reduction in folate stores 
[Kremer et al., 1986]. Product labeling approved by the U.S. Food and Drug Administration 
acknowledges the interpatient variability of methotrexate elimination and recommends 
women of child-bearing potential to delay conception at least one ovulatory cycle after 
discontinuing treatment [U.S. Food and Drug Administration, 2011]. Previous case reports 
have inconsistently described use of folic acid during methotrexate-exposed pregnancies, but 
it has been suggested that use of a folic acid-containing multivitamin may reduce some of 
the adverse effects resulting from use of folic acid antagonists [Hernández-Díaz et al., 
2000].
Our report was limited by several factors. First, the small number of exposed cases 
necessitated a case-series approach and limited our ability to infer an association between 
methotrexate and birth defects. One limitation of case reports is that the likelihood that the 
birth defects were observed by chance cannot be assessed. However, case reports may be 
useful in describing possible embryopathy attributed to a suspected teratogen when similar 
patterns in defects are observed independently across time and study population. Therefore, 
the main objective of this report was to describe methotrexate-exposed cases in the NBDPS 
and compare the defects observed with those that have been described previously.
Second, the reported methotrexate exposure is potentially subject to inaccurate maternal 
recall as the exposures were based on maternal self-report following the delivery of the 
affected offspring. It is possible that women who were exposed to methotrexate during a 
failed pregnancy termination did not know the name of the medication. Because we did not 
specifically ask interviewed mothers about all conditions for which methotrexate is 
indicated, and not all interviewed mothers received the interviewer probe regarding specific 
chronic medical conditions, it is possible that we might have some exposure 
misclassification. We were also not able to separate the effects of the medication from those 
of the underlying conditions. Methotrexate is used in the termination of pregnancy, therefore 
it is likely that we have under-ascertained some cases of major birth defects that resulted in 
spontaneous abortion or fetal death, particularly those deaths that occurred prior to 20 weeks 
gestation. This report excluded infants that had defects that did not meet the NBDPS case 
definition or infants suspected of having a recognizable syndrome, therefore we may have 
under-ascertained cases of minor or non-eligible major birth defects that occurred in the 
source population of NBDPS.
Strengths of this study include use of a population-based sample from ten different states 
across the United States, which provided a demographically diverse sample. We were able 
to examine a wide range of maternal exposures and sociodemographic characteristics. 
Finally, case abstractions were examined by two clinicians.
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In conclusion, based on a limited number of cases, our findings support recent case reports 
suggesting an association between early pregnancy methotrexate exposure and CHD 
[Piggott et al., 2011, Poggi and Ghidini, 2011, Hyoun et al., 2012]. Although our data do not 
provide conclusive evidence that the proposed window of sensitivity to methotrexate 
embryopathy could be expanded, our findings may be helpful to healthcare providers who 
counsel women prenatally exposed to methotrexate. Because of the rarity of maternal 
periconceptional exposure to methotrexate, long-term, population-based case-control studies 
are needed to confirm these findings and better evaluate the association between 
methotrexate and birth defects.
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